Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab
Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab
复制标题
应用动态超声造影选择血管正常化的早期生物标志物预测贝伐单抗治疗的转移性患者的预后
DOI：
10.1093/annonc/mdw280
复制
发表时间：
2016-10-01
影响因子：
50.5
通讯作者：
Koscielny, S.
中科院分区：
文献类型：
--
作者：
Lassau, N.;Coiffier, B.;Koscielny, S.
动态对比增强超声检查是一种功能性技术，能够对接受抗血管生成疗法治疗的转移性患者的实体瘤灌注进行定量评估。在本研究中，我们表明，第 7 天通过 DCE-US 评估的平均通过时间可用作血管正常化生物标志物，以预测接受贝伐单抗治疗的转移性患者的结果。动态对比增强超声检查 (DCE-US) 已用于评估肿瘤对抗血管生成治疗的反应。本研究的目的是评估治疗第一周获得的 DCE-US 数据与随后的肿瘤进展之间的联系。接受抗血管生成治疗的患者被纳入 2007 年至 2010 年的一项多中心前瞻性研究中。DCE-US 检查可在基线和第 7 天进行。对于每次检查，在注射造影剂后立即记录 3 分钟灌注曲线。每条灌注曲线均采用七个参数进行建模。我们分析了截至第 7 天测量的无进展 (FFP) 标准之间的相关性。根据肿瘤定位和治疗类型在全球范围内评估了影响。中位随访时间为 20 个月。第 7 天评估的平均通过时间 (MTT) 是与 FFP 显着相关的唯一标准 (P = 0.002)。最大化 FFP 曲线之间差异的截止点是 12 秒。 MTT 至少为 12 秒的患者具有更好的 FFP。根据肿瘤类型的结果存在显着异质性：与其他肿瘤类型相比，MTT 对 FFP 的影响对于乳腺癌 (P = 0.004) 和结肠癌 (P = 0.025) 更为显着。同样，接受贝伐单抗治疗的患者中，第 7 天根据 MTT 得出的 FFP 差异显着 (P = 0.004)。第 7 天用 DCE-US 评估的 MTT 与贝伐单抗治疗患者的 FFP 显着相关。该标准可能与血管正常化有关。2007-A00399-44。
Dynamic contrast-enhanced ultrasonography is a functional technique enabling quantitative assessment of solid tumor perfusion in metastatic patients treated with antiangiogenic therapies. In this study, we show that the mean transit time evaluated by DCE-US at day 7 may be used as a vascular normalization biomarker to predict the outcome of metastatic patients treated with bevacizumab.Dynamic contrast-enhanced ultrasonography (DCE-US) has been used for evaluation of tumor response to antiangiogenic treatments. The objective of this study was to assess the link between DCE-US data obtained during the first week of treatment and subsequent tumor progression.Patients treated with antiangiogenic therapies were included in a multicentric prospective study from 2007 to 2010. DCE-US examinations were available at baseline and at day 7. For each examination, a 3 min perfusion curve was recorded just after injection of a contrast agent. Each perfusion curve was modeled with seven parameters. We analyzed the correlation between criteria measured up to day 7 on freedom from progression (FFP). The impact was assessed globally, according to tumor localization and to type of treatment.The median follow-up was 20 months. The mean transit time (MTT) evaluated at day 7 was the only criterion significantly associated with FFP (P = 0.002). The cut-off point maximizing the difference between FFP curves was 12 s. Patients with at least a 12 s MTT had a better FFP. The results according to tumor type were significantly heterogeneous: the impact of MTT on FFP was more marked for breast cancer (P = 0.004) and for colon cancer (P = 0.025) than for other tumor types. Similarly, the differences in FFP according to MTT at day 7 were marked (P = 0.004) in patients receiving bevacizumab.The MTT evaluated with DCE-US at day 7 is significantly correlated to FFP of patients treated with bevacizumab. This criterion might be linked to vascular normalization.2007-A00399-44.